Compugen Ltd. (NASDAQ: CGEN) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
Compugen to Participate in Two Upcoming Investor Conferences